Nachrichten zur Karyopharm Therapeutics Inc. Aktie

Karyopharm Therapeutics Inc (KPTI) Q2 2020 Earnings Call Transcript

KPTI earnings call for the period ending June 30, 2020....…

Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q2 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics Inc. 2020 Q2 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

NEWTON, Mass. , Aug. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a…

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , Aug. 3, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an…

Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020

NEWTON, Mass. , July 28, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical…

FDA accepts Karyopharm supplement application for expanded use of Xpovio in multiple myeloma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Is Trading At A Discount After Recent Additional Xpovio Approval

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm teams up with NCI to advance Xpovio research

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research

NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced…

Karyopharm sees Q2 Xpovio sales of $18.5M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)

-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the Second Quarter 2020 -- -- Strongest Quarterly XPOVIO…

Karyopharm up 5% on uncertainty with advisory committee nod for Glaxo drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today…

Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large…

The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions

Biotech stocks rebounded along with the broader market in the week ended June 19. read more...…

Karyopharm Brain Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting

-- Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL…

Karyopharm Starts Dosing in Selinexor Study for Glioblastoma

Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or…

Karyopharm commences study of selinexor in brain cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics (KPTI) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today…

Karyopharm In Pursuit Of Wider Use Of Xpovio

After winning FDA nod for Xpovio in the treatment of relapsed or refractory multiple myeloma, Karyopharm Therapeutics Inc. (KPTI) is…

Karyopharm up 6% on late-stage selinexor data in multiple myeloma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

-- Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to…

Karyopharm to Participate at Jefferies Virtual Healthcare Conference

-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE…

Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program

-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE…

Karyopharm Therapeutics: Getting Paid Well For Accepting Uncertainty

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm submits sNDA for Xpovio as a treatment for multiple myeloma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm files U.S. application for expanded use of Xpovio

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced…

Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society

NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced…

Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference

Fireside Chat Scheduled for Tuesday, May 19, 2020, at 8:35 a.m. ET Fireside Chat Scheduled for Tuesday, May 19, 2020,…

Karyopharm Therapeutics Inc (KPTI) Q1 2020 Earnings Call Transcript

KPTI earnings call for the period ending March 31, 2020....…

Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q1 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do…

Karyopharm Therapeutics Inc. 2020 Q1 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm slips 5% premarket on Q1 miss

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Recap: Karyopharm Therapeutics Q1 Earnings

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) fell 9% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose…

Karyopharm Therapeutics EPS misses by $0.07, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Karyopharm (KPTI) Might Surprise This Earnings Season

Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....…

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today…

Karyopharm teams up with CRO in study of selinexor in COVID-19

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

What Makes Karyopharm Therapeutics (KPTI) a Strong Momentum Stock: Buy Now-

Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Lets find out....…

Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19

BUDAPEST, Hungary , April 22, 2020 /PRNewswire/ -- Precision for Medicine, a pioneer in the…